Education
1970        B.A.        Cornell University
1974        M.D.        Harvard Medical School

Clinical Specialties
Autoimmune blistering skin diseases

Research Area of Interests
Immunodermatology, cell and molecular biology of keratinocyte adhesion, targeted drug delivery.

Research Summary
Dr. Stanley studies the pathophysiology of pemphigus, an autoimmune disease in which autoantibodies cause loss of keratinocyte cell adhesion and blister formation. He has shown that pemphigus antigens are desmosomal cadherins, and has shown that these glycoproteins function in stabilizing cell-cell adhesion in desmosomes. Furthermore, he has characterized the distribution of desmosomal cadherins in the skin and mucous membranes. Using this knowledge he has dissected the molecular pathophysiology of these diseases. By altering the distribution of desmosomal cadherins he has shown protection against disease and determined physiologic functions for desmosomal cadherin isoforms. Finally, Dr. Stanley has determined how exfoliative toxins produced by staphylococcus cause the blisters in bullous impetigo and staphylococcal scalded skin syndrome.

1. Ishii K, Lin C, Siegel DL, Stanley JR: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J. Invest. Dermatol. (in press).

2. Payne AS, Siegel DL, Stanley JR: Targeting pemphigus autoantibodies by their heavy chain variable region genes. J. Invest. Dermatol. 127: 1681-1691, 2007.

3. Stanley JR, Amagai M: Pemphigus, bullous impetigo, and staphylococcal scalded skin syndrome. N. Engl. J. Med. 355:1800-1809, 2006

4. Anzai H, Stanley JR, Amagai M: Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphyloccal scalded skin syndrome. J. Invest. Dermatol. 126: 2139-2141, 2006

5. Heng A, Nwaneshiudu A, Hashimoto T, Amagai M, Stanley JR: Intraepidermal neutrophilic IgA/IgG anti-desmocollin 1 pemphigus. Br. J. Dermatol. 154:1018-1019, 2006

6. Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A: Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol. Chem. 386: 1173-1184, 2005

7. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL: Genetic and functional characterization of human pemphigus vulgaris monoclonal antibodies isolated by phage display. J. Clin. Invest. 115:888-899, 2005

8. Payne AS, Hanakawa Y, Amagai M, Stanley JR: Desmosomes and diseases: pemphigus and bullous impetigo. Curr. Opin. Cell Biol. 16: 536-543, 2004

9. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL: Genetic and functional characterization of human pemphigus vulgaris monoclonal antibodies isolated by phage display. J. Clin. Invest. 115:888-899, 2005

10. Hanakawa, Y., Schechter, N.M., Lin, C., Garza, L., Li, H., Yamaguchi, T., Fudaba, Y., Nishifuji, K., Sugai, M., Amagai, M., and Stanley,J.R. 2002. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J.Clin.Invest. 110:53-60.

11. Elias, P.M., Matsuyoshi, N., Wu, H., Lin, C., Wang, Z.H., Brown, B. E., and Stanley,J.R. 2001. Desmoglein Isform Destribution Affects Stratum Corneum Structure and Function. J.Cell Biol.. 153:243-249.

12. Amagai,M., Matsuyoshi,N., Wang,Z.H., Andl,C., and Stanley,J.R. 2000. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Med. 6:1275-1277.

13. Wu,H., Wang,Z.H., Yan,A., Lyle,S., Fakharzadeh,S., Wahl,J.K., Wheelock,M.J., Ishikawa,H., Uitto,J., Amagai,M., Stanley, J.R. 2000. Protection of neonates against pemphigus foliaceus by desmoglein 3. N.Engl.J.Med. 343:31-35.

14. Stanley,J.R. 1999. Bullous pemphigoid. In Dermatology in General Medicine. T.B.Fitzpatrick, Eisen,A.Z., Wolff,K., Freedberg,I.M., and Katz,S., editors. McGraw-Hill, 666-673.

15. Stanley,J.R. 1999. Therapy of pemphigus vulgaris. Arch.Dermatol. 135:76-78.

16. Udey,M.C. and Stanley,J.R. 1999. Pemphigus: diseases of anti-desmosomal autoimmunity. JAMA 282:572-576, 1999.

17. Stanley,J.R. 1999. Pemphigus. In Fitzpatrick's Dermatology in General Medicine. I.M.Freedberg, Eisen,A.Z., Wolff,K., Austen,K.F., Goldsmith,L.A., Katz,S.I., and Fitzpatrick,T.B., editors. McGraw-Hill, New York. 654-666.

18. Mahoney,M.G., Wang,Z., Rothenberger,K., Koch,P.J., Amagai,M., and Stanley,J.R. 1999. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J.Clin.Invest. 103:461-468.

19. Koch,P.J., Mahoney,M.G., Ishikawa,H., Pulkkinen,L., Uitto,J., Shultz,L., Murphy,G.F., Whitaker-Menezes,D., and Stanley,J.R. 1997. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J.Cell Biol. 137:1091-1102.

20. Amagai,M., Klaus-Kovtun,V., and Stanley,J.R. 1991. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869-877.

21. Stanley,J.R. 1990. Pemphigus: skin failure mediated by autoantibodies. JAMA 264:1714-1717.

22. Korman,N.J., Eyre,R.W., Klaus-Kovtun,V., and Stanley,J.R. 1989. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N.Engl.J.Med. 321:631-635.

23. Stanley,J.R., Koulu,L., Klaus Kovtun,V., and Steinberg,M.S. 1986. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J.Immunol. 136:1227-1230.

24. Koulu,L., Kusumi,A., Steinberg,M.S., Klaus Kovtun,V., and Stanley,J.R. 1984. Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J.Exp.Med. 160:1509-1518.

25. Stanley,J.R., Hawley Nelson,P., Yuspa,S.H., Shevach,E.M., and Katz,S.I. 1981. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 24:897-903.